Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 383-389

  Ren, X S ^a,b   Crivera, C ^c   Sikirica, M ^c   Dirani, R ^c   Qian, S ^a,b   Kazis, L E ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

health services utilization; long acting antipsychotic agents; schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEPATITIS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VETERAN;

ADULT; AGED; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PREVALENCE; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 79955750158     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01211.x     Document Type: Article

References (25)

1. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K, (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 160, 1125-1132. (Pubitemid 41070972)
2. Mohl A, Westlye L, Opjordsmoen S, et al. (2005) Long-acting risperidone in stable patients with schizoaffective disorder. Journal of Psychopharmacology, 19, 22-31. (Pubitemid 41392294)
3. Fleischhacker WW, Eerdekens M, Karcher K, et al. (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry, 64, 1250-1257.
4. Keith SJ, Pani L, Nick B, et al. (2004) Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services, 55, 997-1005. (Pubitemid 39209681)
5. Kane JM, (2003) Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry, 64, 34-40. (Pubitemid 37523326)
6. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS, (2009) Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Current Medical Research and Opinion, 25, 2197-2206.
7. Parellada E, (2007) Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacology Bulletin, 40, 82-100.
8. Lasser RA, Bossie CA, Gharabawi GM, Turner M, (2004) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry, 19, 219-225. (Pubitemid 38766136)
9. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M, (2004) Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Journal of Clinical Psychiatry, 65, 531-536.
10. Muller M, Shermock M, Russo P, Secic M, Dirani D, Vallow S, Flanders S, (2009) Hospitalization and resource utilization in schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Journal of Medical Economics, 12, 317-324.
11. Ren XS, Dirani R, Meletiche DM, Qian S, Rofman ES, Kazis LE, (2007) Initiation of risperidone long-acting injectable and subsequent patient outcomes in the Veterans Health Administration. Poster presented at: 20th Annual US Psychiatric and Mental Health Congress; October 11-14, Orlando, FL.
12. Lamoreaux J, (1996) The organizational structure for medical information management in the Department of Veterans Affairs. An overview of major health care databases. Medical Care, 34, 31-44.
13. Selim AJ, Fincke G, Ren XS, et al. (2004) Comorbidity assessments based on patient report: results from the Veterans Health Study. Journal of Ambulatory Care and Management, 27, 281-295. (Pubitemid 38780398)
14. Veterans Health Administration (2002) Effective treatment for schizophrenia. Practice Matters, 7, 2-5.
15. Department of Veterans Affairs/Department of Defense (2004) Clinical practice guideline management of psychoses. Washington, DC: Department of Veterans Affairs.
16. American Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154, 1-63.
17. Lehman AF, Steinwachs DM, (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10. (Pubitemid 28128486)
18. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin, 30, 193-217. (Pubitemid 38828528)
19. Lambert T, Olivares JM, Tuma I, et al. (2008) Effectiveness of risperidone long acting injection (RLAI) in the treatment of recently versus longer diagnosed patients with schizophrenia:12-month interim results from the electronic schizophrenia treatment adherence registry (e-STAR). Poster presented at: 63rd Annual Scientific Meeting and Convention of the Society of Biological Psychiatry; May 1-3, Washington, DC.
20. Macfadden W, Bossie C, Turkoz I, Dorson P, Haskins JT, (2008) Effect of long-acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness. Poster presented at: American Psychiatric Association Annual Meeting; May 5-8, Washington, DC.
21. Ren XS, Qian S, Lee AF, Herz L, Miller DR, Kazis LE, (2006) Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. Journal of Clinical Pharmacy and Therapeutics, 31, 57-65.
22. Ren XS, Herz L, Qian S, Smith E, Kazis LE, (2009) Measurement of treatment persistence with antipsychotic agents in patients with schizophrenia. Neuropsychiatric Disease and Treatment, 5, 491-498.
23. Tafesse E, Hines PL, Carson W, (2003) Atypical antipsychotic adherence and hospitalization in patients with schizophrenia. Schizophrenia Research, 60, 346.
24. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV, (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892-909. (Pubitemid 35231730)
25. Knapp M, (2000) Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatrica Scandinavica, 102, 15-18.